Abstract
Crohn’s disease (CD) and ulcerative colitis (UC) are the two major subtypes of inflammatory bowel disease (IBD). Hematological changes, including anemia, hypercoagulable state, thrombocytosis, leukocytosis, and acute or chronic forms of leukemia, have been reported in IBD patients [1]. Patients with IBD are also suspected of being at increased risk of malignant lymphomas, especially non-Hodgkin’s lymphoma (NHL), as of other inflammatory disorders, namely rheumatoid arthritis (RA), Sjögren syndrome, and systemic lupus erythematosus (SLE) [2]. In all these conditions, as in IBD, the respective role of chronic inflammation and of immunosuppressive treatment in the development of lymphomas has not been elucidated, although the role of the immune system in the development of malignant disorders, especially lymphomas, is well recognized.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Caspi O, Polliack A, Klar R et al (1995) The association of inflammatory bowel disease and leukemia — coincidence or not? Leuk Lymphoma 17:255–262
Leandro MJ, Isenberg DA (2001) Rheumatic diseases and malignancy — is there an association? Scand J Rheumatol 30:185–188
Gridley G, Mc Laughlin JK, Ekbom A et al (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307–311
Farrell RJ, Ang Y, Kileen P et al (2000) Increased incidence of non-Hodgkin’s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 47:514–519
Pearson DC, May GR, Fick GH et al (1995) Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123:132–142
Feagan BG, Fedorak RN, Irvine EJ et al (2000) A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 342:1627–1632
Cominelli F (2004) Cytokine-based therapies for crohn’s disease — new paradigms. N Engl J Med 351:2045
Aithal GP, Mansfield JC (2001) The risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment. Aliment Pharmacol Ther 15:1101–1108
Lewis JD, Bilker WB, Brensinger C et al (2001) Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121:1080–1088
Askling J, Brandt L, Lapidus A et al (2005) Risk of haematoepoietic cancer in patients with inflammatory bowel disease. Gut 54:617–622
Hemmiki K, Li X, Sundquist J et al (2009) Cancer risk in Crohn disease patients. Ann Oncol 20:574–580
Voon Roon AC, Reese G, Teare J et al (2007) The risk of cancer in patients with Crohn’s disease. Dis Colon Rectum 50:839–855
Dayharsh GA, Loftus EV, Sandborn WJ et al (2002) Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 122:72–77
Wakefield AJ, Fox JD, Sawyerr AM et al (1992) Detection of herpesvirus DNA in the large intestine of patients with ulcerative colitis and Crohn’s disease using the nested polymerase chain reaction. J Med Virol 38:183–190
Kandiel A, Fraser AG, Korelitz BI et al (2005) Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54:1121–1125
Lewis JD, Schwartz JS, Lichtenstein GR (2000) Azathioprine for maintenance of remission in Crohn’s disease: benefits outweight the risk of lymphoma. Gastroenterology 118:1018–1024
Bongartz T, Sutton AJ, Sweeting MJ et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285
Kinney T (2003) Immunomodulators and “on demand” therapy with infliximab in Crohn’s disease: clinical experience with 400 infusions. Am J Gastroenterol 98:608–612
Colombel JF, Loftus EV Jr, Tremaine WJ et al (2004) The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 126:19–31
Ljung T, Karlen P, Schmidt D et al (2004) Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 53:849–853
Biancone L, Orlando A, Kohn A et al (2006) Infliximab and newly diagnosed neoplasia in Crohn’s disease: a multicentre matched pair study. Gut 55:228–233
Lichtestein GR, Feagan BG, Cohen RD et al (2006) Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 4:621–630
Siegel CA, Hur C, Korzenik JR et al (2006) Risks and benefits of infliximab for the treatment of Crohn’s disease. Clin Gastroenterol Hepatol 4:1017–1024
Mittal S, Milner BJ, Johnston PW et al (2006) A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur J Haematol 76:531–534
Thayu M, Markowitz JE, Mamula P et al (2005) Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn’s disease. J Pediatr Gastroenterol Nutr 40:220–222
Rosh J R, Gross T, Mamula P, Griffiths A, Hyams J. (2007) Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis 13:1024–1030
Wöhrer S, Troch M, Zwerina J et al (2007) Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. Ann Oncol 18:647–651
Michallet AS, Coiffier B (2009) Recent developments in the treatment of aggressive non-Hodgkin lymphoma. Blood Rev 23 (1):11–23
Maloney D (2008) Allogeneic transplantation following non-myeloablative conditioning for aggressive lymphoma. Bone Marrow Transplant (Suppl 1):535–536
Ladetto M, De Marco F, Benedetti F et al (2008) Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in hig-risk follicular lymphoma at diagnosis: the superior disease control of RHDS does not translate into an overall survival advantage. Blood 111:4004–4013
Fortun PJ & Hawkey CJ. (2008) The role of stem cell transplantation in inflammatory bowel disease. Autoimmunity 41 (8):654–659
Castro J, Bentch H, Smith L et al (1996) Prolonged clinical remission in patient with inflammatory bowel disease (IBD) after high dose chemotherapy (HDC) and autologous bood stem cell transplantation (ABSCT). Blood 88 (Supplement):133A
Anumakonda V, Hayee B, Chung-Faye (2007) Remission and relapse of Crohn’s disease following autologous haematopoietic stem cell transplantation for non-Hodgkin’s lymphoma. Gut 56:1325
Oyama Y, Craig RM, Traynor AR et al (2005) Autologous hematopoietic stem cell transplantation in patients with refractory Crohns disease. Gastroenterology 128:552–563.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Italia
About this chapter
Cite this chapter
Zoli, V., Proia, A., Majolino, I. (2010). Crohn’s Disease and Malignant Lymphomas. In: Tersigni, R., Prantera, C. (eds) Crohn’s Disease. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-1472-5_25
Download citation
DOI: https://doi.org/10.1007/978-88-470-1472-5_25
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1471-8
Online ISBN: 978-88-470-1472-5
eBook Packages: MedicineMedicine (R0)